CONMED Corporation (CNMD)
NYSEHealth CareMedical - DevicesSnapshot 2026-11-05
$52.83-1.55%
Close 2026-11-05 · 1-day change
NYSEHealth CareMedical - DevicesSnapshot 2026-11-05
QuarterlyIQ Insights · CNMD
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -42.6% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Usually moved in the opposite direction.
Price observations: 365 days
Most sensitive to the broad stock market and long-term interest rates.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 3.6% |
Growth built into the price is above our model estimate.
The price assumes 46.2 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-05 · Compared with 42 industry peers · Company calendar date is not available
CNMD — debt issuance
Dated 2026-06-04
Entry into a Material Definitive Agreement. On June 3, 2026, CONMED Corporation, a Delaware corporation (“ CONMED ”), entered into separate, privately negotiated purchase agreements (the “ Purchase Agreements ”) with certain holders of its 2.25% Convertible Senior Notes due 2027 (the “ Notes ”). Under the terms of the Purchase Agreements, the Company agreed to purchase approximately $645.2 million aggregate principal amount of Notes from the holders thereof for approximately $637.2 million in…
Why it matters: U.S. General Surgery sales fell 14.4% as reported in Q3. A smaller drop would show the weak area is easing.
Worry ifU.S. General Surgery sales fall at least 10% year over year on a reported basis in the next quarter.
Less concerning ifU.S. General Surgery sales are flat or higher year over year on a reported basis in the next quarter.
Why it matters: Q3 adjusted EPS beat management’s expectations, and the full-year range was raised slightly. The next report will test whether that gain holds.
Supportive ifFull-year 2026 adjusted diluted EPS is at least $4.54, within the updated $4.54–$4.61 range.
Worry ifFull-year 2026 adjusted diluted EPS is below $4.54, or guidance is cut below that level.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$148 on $10,000 · ±1.5% | How much price usually moves either way. |
| Bad day | $404 loss on $10,000 · 4.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,029 loss on $10,000 · 30.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.